Valeant Withheld Documents in Price Probe, Congress Says
- House oversight committee seeks reason for missing information
- Drugmaker has provided only `nonprivileged' documents
Valeant CEO Meets With Top Execs After Medical Leave
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. hasn’t given members of Congress all the documents they have sought as part of a probe into the company’s drug pricing practices, and lawmakers want to know why.
Leaders of the House Committee on Oversight and Government Reform wrote to Valeant Chief Executive Officer Michael Pearson on Thursday, asking him to explain why the drugmaker hasn’t turned over the information originally requested in August, according to a statement from Committee Chairman Jason Chaffetz, a Republican from Utah, and the ranking Democrat on the committee, Representative Elijah Cummings of Maryland.